Poseida Therapeutics, Inc.
Poseida Therapeutics, Inc. (PSTX) Revenue
Annual & quarterly revenue history · segment & region breakdown
PSTX · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsPoseida Therapeutics, Inc. trailing twelve-month (TTM) revenue is $0.15B, a decrease of 50.37% year-over-year from $0.06B in FY2023.
Revenue trend
2023 – 2016 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2023-12-31 | $0.06B | -$0.07B | -50.37% |
| 2022-12-31 | $0.13B | +$0.13B | +417217.08% |
| 2021-12-31 | $0.00B | +$0.00B | — |
| 2020-12-31 | $0.00B | +$0.00B | — |
| 2019-12-31 | $0.00B | +$0.00B | — |
| 2018-12-31 | $0.00B | -$0.00B | -100.00% |
| 2017-12-31 | $0.00B | -$0.01B | -69.44% |
| 2016-12-31 | $0.01B | — | — |
Compare revenue vs peers
BiotechnologyCompare PSTX revenue against listed peers. Click any row to open that company's revenue tab.
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Poseida Therapeutics, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Poseida Therapeutics, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Poseida Therapeutics, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
PSTX revenue · 4 questionsPSTX's trailing twelve-month (TTM) revenue is $0.15B. That is a decrease of 50.37% year-over-year from $0.06B in FY2023.
▸ Source: FMP · Poseida Therapeutics, Inc. SEC filings · GAAP · Poseida Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026